Literature DB >> 31256682

A safe treatment for congenital fibrovascular pupillary membrane.

Qiwei Wang1, Fengqi Zhou1,2, Wan Chen1, Jingjing Chen1, Zhenglong Ouyang1, Zhuoling Lin1, Xiaoyan Li1, Haotian Lin1, Weirong Chen1.   

Abstract

PURPOSE: The purpose of this study was to describe the clinical features and management of fibrovascular pupillary membrane.
METHODS: Four patients with congenital fibrovascular pupillary membrane were recruited. Comprehensively, ophthalmic examinations were performed. Peripheral iridectomy was performed to create a tunnel for blunt dissection of adhesion between the membrane and the lens capsule. Bipolar radiofrequency diathermy was then used to cut the membrane utilizing its coagulation effect.
RESULTS: All four patients received uneventful membranectomy surgeries. The follow-up duration ranged from 9 to 16 months. All patients recovered well. Visual behavior was central and steady. The natural pupil size ranged from 2 to 3 mm. No sign of visual axis obstruction, cataract formation, or intraocular pressure elevation was detected during the follow-up. No second surgery was needed for all patients.
CONCLUSION: Fibrovascular pupillary membrane is a rare unilateral disease impairing visual acuity in children. Using the technique combining peripheral iridectomy with bipolar radiofrequency, diathermy can simplify the traditional surgery procedures and reduce the risks when removing fibrovascular pupillary membranes.

Entities:  

Keywords:  Congenital fibrovascular pupillary membrane; bipolar radiofrequency diathermy; lens damage; peripheral iridectomy

Mesh:

Year:  2019        PMID: 31256682     DOI: 10.1177/1120672119859666

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  1 in total

1.  Congenital fibrovascular pupillary membranes: case series with pathological correlation and surgical treatment.

Authors:  Yi Zhou; Cong Fan; Xiao-Bo Xia; Jian Jiang
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.